Special Issue

Chemokines and Chemokine Receptors

Message from the Guest Editor

Chemokines are proinflammatory chemoattractant cytokines that play a fundamental role in a multitude of physiological processes, besides being primarily involved in leukocyte trafficking. Around 45 drugs targeting chemokine receptors have been developed. vet only three are clinically approved. The major limitation in this field is the complex nature of aberrant chemokine signaling, which makes it difficult to understand the redundancy of chemokine receptorligand binding. Besides being involved in disease pathogenesis, chemokine signaling plays a critical role in many physiological processes that pose an additional challenge. Moreover, the broad ligand-binding pockets of chemokine receptors makes it difficult to design highly specific antagonists leading to non-specific binding, which may pose debilitating off-target effects. In this Special Issue, authors are invited to submit their original and review articles that provide mechanistic insights into the chemokine system and highlight some potential strategies in the future development of chemokine-directed therapy. I look forward to your valuable contributions.

Guest Editor

Dr. Neeraj Kapur

Division of Digestive Diseases and Nutrition, University of Kentucky College of Medicine, Lexington, KY, USA

Deadline for manuscript submissions

closed (30 April 2024)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/151018

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

